Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions - Additional Information (Detail)

v3.19.1
Related Party Transactions - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 25, 2019
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Underwritten Public Offering [Member] | Common Stock [Member]        
Related Party Transaction [Line Items]        
Number of common stock issued in offering 16,666,668      
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Common Stock [Member]        
Related Party Transaction [Line Items]        
Number of common stock issued in offering 100,000      
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Short-term Warrants [Member]        
Related Party Transaction [Line Items]        
Number of warrants purchased in period 50,000      
Dr. Frederick Telling, Chairman and Director [Member] | Underwritten Public Offering [Member] | Long-term Warrants [Member]        
Related Party Transaction [Line Items]        
Number of warrants purchased in period 50,000      
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Common Stock [Member]        
Related Party Transaction [Line Items]        
Number of common stock issued in offering 66,667      
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Short-term Warrants [Member]        
Related Party Transaction [Line Items]        
Number of warrants purchased in period 33,333      
Dr. Alan Joslyn, Chief Executive Officer and President [Member] | Underwritten Public Offering [Member] | Long-term Warrants [Member]        
Related Party Transaction [Line Items]        
Number of warrants purchased in period 33,333      
Intrexon [Member]        
Related Party Transaction [Line Items]        
Accounts payable and accrued expenses   $ 61,905   $ 39,607
Percentage of outstanding common stock   3.36% 29.80%  
Intrexon [Member] | Oral Mucositis and Lantibiotic ECC [Member]        
Related Party Transaction [Line Items]        
Cash paid to Intrexon Corporation   $ 39,607 $ 78,606